FK 352

Drug Profile

FK 352

Alternative Names: FK 352B

Latest Information Update: 31 Aug 2015

Price : $50

At a glance

  • Originator Fujisawa
  • Class Neuroprotectants; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypotension; Renal failure

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 31 Jan 2005 This compound is still in active development for hypotension
  • 16 Jun 2004 Data presented at the 41st Congress of the European Renal Association and the European Dialysis and Transplant Association (ERA-EDTA-2004) have been added to the Vascular Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top